181 related articles for article (PubMed ID: 21890454)
1. Species D adenoviruses as oncolytics against B-cell cancers.
Chen CY; Senac JS; Weaver EA; May SM; Jelinek DF; Greipp P; Witzig T; Barry MA
Clin Cancer Res; 2011 Nov; 17(21):6712-22. PubMed ID: 21890454
[TBL] [Abstract][Full Text] [Related]
2. Infection and killing of multiple myeloma by adenoviruses.
Senac JS; Doronin K; Russell SJ; Jelinek DF; Greipp PR; Barry MA
Hum Gene Ther; 2010 Feb; 21(2):179-90. PubMed ID: 19788385
[TBL] [Abstract][Full Text] [Related]
3. Mining the adenovirus virome for oncolytics against multiple solid tumor types.
Chen CY; Weaver EA; Khare R; May SM; Barry MA
Cancer Gene Ther; 2011 Oct; 18(10):744-50. PubMed ID: 21886190
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic virotherapy for osteosarcoma using midkine promoter-regulated adenoviruses.
Takagi-Kimura M; Yamano T; Tagawa M; Kubo S
Cancer Gene Ther; 2014 Mar; 21(3):126-32. PubMed ID: 24577130
[TBL] [Abstract][Full Text] [Related]
5. Comparison of adenoviruses as oncolytics and cancer vaccines in an immunocompetent B cell lymphoma model.
Weaver EA; Chen CY; May SM; Barry ME; Barry MA
Hum Gene Ther; 2011 Sep; 22(9):1095-100. PubMed ID: 21770794
[TBL] [Abstract][Full Text] [Related]
6. Mining the adenovirus "virome" for systemic oncolytics.
Barry MA; Weaver EA; Chen CY
Curr Pharm Biotechnol; 2012 Jul; 13(9):1804-8. PubMed ID: 21740366
[TBL] [Abstract][Full Text] [Related]
7. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts.
Radhakrishnan S; Miranda E; Ekblad M; Holford A; Pizarro MT; Lemoine NR; Halldén G
Hum Gene Ther; 2010 Oct; 21(10):1311-25. PubMed ID: 20497039
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic adenoviruses: design, generation, and experimental procedures.
Davydova J; Yamamoto M
Curr Protoc Hum Genet; 2013 Jul; Chapter 12():Unit 12.14. PubMed ID: 23853080
[TBL] [Abstract][Full Text] [Related]
10. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
[TBL] [Abstract][Full Text] [Related]
11. Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus.
Bazan-Peregrino M; Carlisle RC; Hernandez-Alcoceba R; Iggo R; Homicsko K; Fisher KD; Halldén G; Mautner V; Shen Y; Seymour LW
Hum Gene Ther; 2008 Sep; 19(9):873-86. PubMed ID: 18710328
[TBL] [Abstract][Full Text] [Related]
12. Virotherapy using a novel chimeric oncolytic adenovirus prolongs survival in a human pancreatic cancer xenograft model.
Chu QD; Sun G; Pope M; Luraguiz N; Curiel DT; Kim R; Li BD; Mathis JM
Surgery; 2012 Sep; 152(3):441-8. PubMed ID: 22853858
[TBL] [Abstract][Full Text] [Related]
13. Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents.
Shashkova EV; May SM; Barry MA
Virology; 2009 Nov; 394(2):311-20. PubMed ID: 19765790
[TBL] [Abstract][Full Text] [Related]
14.
Hemsath JR; Liaci AM; Rubin JD; Parrett BJ; Lu SC; Nguyen TV; Turner MA; Chen CY; Cupelli K; Reddy VS; Stehle T; Liszewski MK; Atkinson JP; Barry MA
J Virol; 2022 Feb; 96(3):e0082621. PubMed ID: 34787457
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models.
Ganesh S; Gonzalez-Edick M; Gibbons D; Van Roey M; Jooss K
Clin Cancer Res; 2008 Jun; 14(12):3933-41. PubMed ID: 18559615
[TBL] [Abstract][Full Text] [Related]
16. A novel Golgi protein (GOLPH2)-regulated oncolytic adenovirus exhibits potent antitumor efficacy in hepatocellular carcinoma.
Wang Y; Liu T; Huang P; Zhao H; Zhang R; Ma B; Chen K; Huang F; Zhou X; Cui C; Liu X
Oncotarget; 2015 May; 6(15):13564-78. PubMed ID: 25980438
[TBL] [Abstract][Full Text] [Related]
17. Expression of human CD46 and trans-complementation by murine adenovirus 1 fails to allow productive infection by a group B oncolytic adenovirus in murine cancer cells.
Lei J; Jacobus EJ; Taverner WK; Fisher KD; Hemmi S; West K; Slater L; Lilley F; Brown A; Champion B; Duffy MR; Seymour LW
J Immunother Cancer; 2018 Jun; 6(1):55. PubMed ID: 29898782
[TBL] [Abstract][Full Text] [Related]
18. In vitro primary cell culture as a physiologically relevant method for preclinical testing of human oncolytic adenovirus.
Adamson RE; Frazier AA; Evans H; Chambers KF; Schenk E; Essand M; Birnie R; Mitry RR; Dhawan A; Maitland NJ
Hum Gene Ther; 2012 Feb; 23(2):218-30. PubMed ID: 21823897
[TBL] [Abstract][Full Text] [Related]
19. Photoactivatable oncolytic adenovirus for optogenetic cancer therapy.
Hagihara Y; Sakamoto A; Tokuda T; Yamashita T; Ikemoto S; Kimura A; Haruta M; Sasagawa K; Ohta J; Takayama K; Mizuguchi H
Cell Death Dis; 2020 Jul; 11(7):570. PubMed ID: 32703933
[TBL] [Abstract][Full Text] [Related]
20. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
